SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT) is trending as the community highlights its recent incorporation of the Aventus DAO in the UAE, the appointment of a strategic advisor to boost regional growth, and the launch of Aventus Cloud. Investors are actively discussing the potential for a major breakout, pointing to the project's low market capitalization, enterprise-grade technology, and Polkadot integration as signs that the asset is currently undervalued.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as traders closely monitor the legal and political battle over the Santa Ynez pipeline restart, with significant debate surrounding the Trump administration's efforts to invoke the Defense Production Act to bypass California's state regulatory restrictions. Community discussions are heavily focused on the high short interest and the potential for a major short squeeze, as investors weigh the company's federal support against ongoing local legal opposition.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a surge in market activity driven by the growing demand for modular, off-grid power solutions in AI data centers, further fueled by a strategic partnership with Sustainable Development Capital LLP targeting 450 megawatts of capacity. While investors remain highly critical of past dilution and the lack of signed contracts, sentiment is shifting as market participants focus on the company's established carbon capture technology and its potential to alleviate energy infrastructure bottlenecks.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is currently seeing heavy community debate as it prepares for a 1-for-5 reverse stock split, with investors divided between those viewing the move as a necessary stabilization and others calling it a sign of ongoing NAV erosion. While some users emphasize the ETF's weekly income potential and pairing strategies with WNTR, many participants are expressing frustration over the decline in share price and dividend distributions relative to the underlying MicroStrategy performance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is seeing intense volatility and record-breaking retail interest as ongoing conflict in the Middle East disrupts the Strait of Hormuz, driving concerns over global supply shocks. While institutional traders weigh the risk of sustained energy inflation against potential government interventions and supply-side waivers, the community remains divided between those betting on further price spikes due to geopolitical escalation and those bracing for a potential correction if diplomacy or strategic releases intervene.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

United Parcel Service is experiencing a notable technical breakout and momentum shift as investors lean into its high dividend yield and turnaround narrative despite ongoing labor union disputes and Amazon volume reductions. The market is actively debating whether recent cost-cutting measures, including workforce and facility consolidations, position the company for a sustained recovery toward higher price levels or if persistent headwinds will continue to weigh on long-term performance.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility as investors weigh a strong earnings beat against ongoing concerns regarding long-term revenue growth. While the company continues to secure multi-billion dollar private connectivity fabric deals, the community remains divided between those accumulating shares during this downturn based on the AI infrastructure narrative and those skeptical of the timeline for financial results.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing significant market interest driven by robust Q3 earnings, record ASCENIV demand, and raised full-year guidance that signals strong growth momentum. The community is actively debating the stock's long-term valuation, with many investors pointing to upcoming pediatric pipeline developments and the potential for a strategic buyout as key catalysts for a move toward higher price levels.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is experiencing significant market attention and upward momentum following the announcement of a full notice to proceed on a 2.4 billion dollar AI data center power project. Investors are actively debating the company's long-term growth potential and the strategic significance of its partnership with Siemens Energy, while navigating noise from short-seller reports.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending as investors digest the recent $5.8 billion merger deal with Valaris, which community members view as a strategic move to create an offshore drilling powerhouse with increased pricing power. The stock is seeing significant options activity and strong retail interest ahead of upcoming earnings, with many focusing on the potential for debt reduction, a strengthening contract backlog, and the sector's long-term recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field.”</li><li>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.&nbsp;</li><li>BioNTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies.</li></ul>Shares of BioNTech SE (BNTX) rose 3% on Friday after Goldman Sachs upgraded the stock to ‘Buy’ from ‘Neutral’.Goldman also raised the price target on the stock to $142, up from $115, according to TheFly. The new price target represents a potential upside of about 34% from the stock’s closing price on Thursday. &nbsp;<h2 class="st-heading-2">Goldman’s Rationale</h2>With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments occurring in the oncology field” and uniquely positioned to develop novel combination approaches to transform cancer care.Data unlocks in 2026 could position the company with “a leading foothold in an emerging wave of new product cycles,” the analyst added.<h2 class="st-heading-2">Pipeline</h2>BioNTech is now looking to strengthen its oncology portfolio as it pivots away from its Covid-19 vaccine Comirnaty developed with Pfizer.BionTech’s oncology pipeline comprises late-stage candidates spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. It is also developing several combination approaches.In 2026, the company expects seven late-stage data readouts, and also looks forward to applying to the U.S. Food and Drug Administration (FDA) for approval of its drug T-Pam in endometrial cancer. BioNTech hopes to become a multi-product oncology company by 2030.The company, however, does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BNTX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user, however, highlighted concerns with the company’s recent acquisition of CureVac. BioNTech closed the acquisition of CureVac in December after<a href="https://stocktwits.com/news-articles/markets/equity/biontech-to-acquire-curevac-in-all-stock-deal-valued-at-1.25-billion/chlXz8nRb6u"> announcing </a>the all-stock deal in June to support its oncology strategy.<stembedurl>https://www.stocktwits.com/taxplanr/message/642106083</stembedurl><a href="https://stocktwits.com/symbol/BNTX">BNTX stock</a> has fallen 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/genmab-reports-mixed-results-from-late-stage-trial-of-lymphoma-drug/cmUmGfeR4Bt">Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio

Goldman raised the price target on BioNTech SE to $142, up from $115.

Equity

Goldman Sachs ETF Trust - Goldman Sachs Innovate Equity ETF

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

GINN
Goldman Sachs ETF Trust - Goldman Sachs Innovate Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GINN News

GINNGoldman Sachs ETF Trust - Goldman Sachs Innovate Equity ETF